Compare iShares Core High Dividend ETF (HDV) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares Core High Dividend ETF trades at $29.08, while IDEXX Laboratories, Inc. trades at $571.39 (market cap $46.22B). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| HDV | IDXX | |
|---|---|---|
52-Week High | $29.14 | $766.68 |
52-Week Low | $23.64 | $526.44 |
Market Cap | — | $46.22B |
Sector | — | Health |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $29.04, up 0.17% with a bullish technical signal from moving averages. The ETF focuses on high-quality dividend stocks, delivering a 3.1% yield while outperforming the S&P 500 by 9 percentage points year-to-date. Recent institutional buying includes Bay Colony Advisors increasing holdings by 370.7% and 180 Wealth Advisors by 386.2% in Q2 2026. Technical indicators show strong momentum with RSI at 76.33 suggesting overbought conditions, while support and resistance cluster around $29.
HDV offers attractive income generation through quality dividend stocks, with defensive sector exposure providing stability. The ETF's screening methodology favors companies with sustainable dividends and strong balance sheets. Key risks include interest rate sensitivity and sector concentration in healthcare and energy. Current technical overbought conditions may limit near-term upside potential despite strong institutional interest.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
